Inhibition of human neuroblastoma cell growth by CAY10404, a highly selective Cox-2 inhibitor

Bhupesh Parashar1, Sai Latha Shankar, Kathleen O'Guin

  • 1Department of Radiation Oncology, Montefiore Medical Center, Bronx, NY 10461, USA.

Journal of Neuro-Oncology
|February 4, 2005
PubMed

Insights

A selective cyclooxygenase-2 (Cox-2) inhibitor, CAY10404, effectively reduced neuroblastoma cell viability and induced apoptosis. This compound also demonstrated radiosensitizing effects, enhancing cell death when combined with irradiation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Neuroblastomas are a significant cause of childhood cancer mortality, accounting for 10% of cases and 15% of deaths.
  • Understanding novel therapeutic targets and mechanisms for neuroblastoma treatment is crucial.

Purpose of the Study:

  • To evaluate the efficacy of CAY10404, a selective cyclooxygenase-2 (Cox-2) inhibitor, in human neuroblastoma cell lines.
  • To elucidate the mechanism of cell death induced by CAY10404.

Main Methods:

  • Treatment of four human neuroblastoma cell lines (SH-EP, SH-SY5Y, SK-N-MC, MSN) with CAY10404.
  • Assessing cell viability, apoptosis (TUNEL, PARP cleavage, caspase-3 activity), cell cycle progression (FACS), and radiosensitization.
  • Western blot analysis to detect protein cleavage indicative of apoptosis.

Main Results:

  • CAY10404 demonstrated a dose-dependent decrease in cell number with an IC50 of 60 microM.
  • Apoptotic cell death was confirmed by TUNEL positivity, PARP cleavage, and increased caspase-3 activity.
  • CAY10404 treatment led to cell cycle arrest in the G2 phase and showed radiosensitizing effects on radioresistant SH-EP cells.

Conclusions:

  • CAY10404 effectively inhibits neuroblastoma cell growth and induces apoptosis through caspase activation.
  • CAY10404 exhibits radiosensitizing properties, suggesting its potential as an adjuvant therapy in neuroblastoma treatment.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...